摘要
Abstract
Objective To investigate the efficacy of etanercept in the treatment of ankylosing spondylitis (AS) and the application value of thalidomide combined with sulfasalazine in its subsequent therapy. Methods 66 cases of AS in our hospital from march 2010 to march 2013 were randomly divided into the group A, B and C. All the patients in 3 groups were treated with etanercept for 3 months;then the group A, B and C were given thalidomide, sulfasalazine and thalidomide combined with sulfasalazine for 3 - month subsequent therapy respectively. The changes of the Bath Ankylosing Spondylitis Disease Activity IndeX (BASDAI) score, Bath Ankylosing Spondylitis Functional IndeX (BASFI) score, erythrocyte sedimentation rate (ESR) and C - reactive protein (CRP) before and after treatment were observed, and the reaction standard recommended by AS Assessment Working group (ASAS) was used to evaluate clinical reactions of patients and the proportion of the patients reaching ASAS20 after treatment were recorded. Results After 3 - month treatment, the BAS-DAI score, BASFI score, ESR and CRP in the three groups were decreased compared with before treatment( P < 0. 05), but the BASDAI score, BASFI score, ESR and CRP had no statistically significant differences among the three groups( P > 0. 05); after 5, 6 months treat-ment, the BASDAI score, BASFI score, ESR and CRP of the group C were significantly lower than those of the group A and B with statistical differences( P < 0. 05) . After etanercept treatment for three months, the proportions of the patients reaching ASAS 20 in the three groups were all 100% , but then after 3 - month different subsequent therapies, the proportion of the group A and B reaching ASAS 20 was significantly decreased, the proportion of group C was significantly higher than that of the group A and B, the difference was statistically significant( P < 0. 05) . Conclusion Etanercept has better efficacy in short - term treatment of AS and can relieve the clinical symptoms quickly and effectively, but the eXpensive price limits its long - term use; in the subsequent therapy, the combination therapy of thalidomide and sulfasalazine can effectively control the symptoms, its effect is significantly better than that of thalidomide or sulfasalazine alone, and its security and tolerance are well, which is worthy of clinical application.关键词
依那西普/强直性脊柱炎/后续治疗/沙利度胺/柳氮磺吡啶Key words
etanercept/ankylosing spondylitis/subsequent treatment/thalidomide/sulfasalazine分类
医药卫生
